Cancer registries
czech english

Please note: Data collection for the registry has been terminated.

The BREAST registry is a non-interventional post-registration database focused on collection of epidemiological and clinical data of patients with breast carcinoma treated with targeted therapies in the Czech Republic. The project was initiated in July 2011 by the Czech Society for Oncology. Obtained data allow for monitoring of CRC patients' treatment and its results. Institute of Biostatistics and Analyses Ltd, a spin-off company of the Masaryk University, provides management and other services to this project.

Primary goals

  • Monitoring of total numbers of patients with breast carcinoma in the Czech Republic treated with bevacizumab, lapatinib, trastuzumab, and everolimus
  • Safety evaluation of the drugs monitored
  • Effectiveness evaluation of the treatment and therapy regimens used

Secondary goals

  • Analysis of patients' survival in relation to clinical factors observed
  • Analysis of patients treated with targeted therapy in relation to Czech population-based reference data


In association with increasing number of the targeted therapies approved for treatment of breast carcinoma, several clinical registries have been developed, which were focused on treatment with individual targeted agents for this indication. Board of the Czech Society for Oncology at the CzMA therefore agreed to solve this situation by development of a new registry, which would integrate data collected within the frame of previous projects. Thus, the BREAST registry has currently served for monitoring of treatment by three targeted agents together - bevacizumab (Avastin), labatinib (Tyverb), trastuzumab (Herceptin), and everolimus (Afinitor). In case of approval of further drugs for the treatment of breast carcinoma, these will be easily included in the registry structure.

Witin the frame of the original registries integration, previously collected data were transferred into the new BREAST registry structure. The integration has removed necessity to enter data on particular patient's treatment into different registries, which allows for obtaining comprehensive and transparent information about overall treatment of the patient, monitoring of therapy sequences and patient's response to the treatment.

The project will undoubtedly increase quality and effectiveness of data collection and simplify work of registry users. Besides of patients' epidemiological characteristics, it will also allow for modelling of risk factors for patients' survival and analysis of adverse effects. The registry may also serve for economical purposes and estimations, such as planning of costs for anticancer treatment.